Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas

Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia

November 2019

6nonenoneZAJA, Francesco; Russo D; Marin L; Silvestri F; Ramello M; Baccarani M.Zaja, Francesco; Rus...

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

Sacchi, Stefano
Pozzi, Samantha
Marcheselli, Raffaella
Federico, Massimo
Tucci, A
Merli, F
Orsucci, L
Liberati, M
Vallisa, D
Brugiatelli, M.

January 2007

The current study was conducted to asses the safety profile and clinical activity of rituximab in co...

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas : phase 2 study of the Italian Lymphoma Foundation

A. Ferrario
A. Pulsoni
B. Olivero
G. Rossi
U. Vitolo
A. Tedeschi
F. Merli
L. Rigacci
C. Stelitano
M. Goldaniga
D. Mannina
P. Musto
F. Rossi
E. Gamba
L. Baldini

August 2012

BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell pro...

Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin’s lymphoma

Hendry, L
Bowen, A
Matutes, E
Swansbury, J
Catovsky, D

May 2004

A regimen combining fludarabine, cyclophosphamide and mitoxantrone (FCM) was used to treat 29 patien...

Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients.

SACCHI, Stefano
LUMINARI, Stefano
FEDERICO, Massimo
Alessandra Tucci
Francesco Merli
Loretta Orsucci
Giulia Cervetti
Ubaldo Occhini
Marina Liberati
Giuseppe Tarantini
Vicenzo Callea
Maura Brugiatelli
Vito Michele Lauta
Luca Baldini

January 2002

Both Cyclophsphamide (C) and Fludarabine (F) have individual anti-lymphoma activity and the combinat...

Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma

Zinzani PL.

January 2004

Fludarabine, a purine nucleoside analog, is currently indicated for the first-line treatment of chro...

FLUDARABINE AND CYCLOPHOSPHAMIDE FOR THE TREATMENT OF PATIENTS WITH INDOLENT NON-FOLLICULAR (INFL) B-CELL NON-HODGKIN'S LYMPHOMAS. PRELIMINARY RESULTS OF A PHASE II TRIAL OF THE 'GRUPPO ITALIANO PER LO STUDIO DEI LINFOMI (GISL)

Luminari, Stefano
L., Baldini
M., Brugiatelli
M., Goldaniga
Sacchi, Stefano
A., Bagnulo
F., Merli
C., Stelitano
G., Giglio
Federico, Massimo

January 2004

Introduction: INFL comprises a rather heterogeneous subgroup of lymphomas,including small lymphocyti...

Fludarabine and prednisone in pretreated refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages

G. DE ROSSI
F. MAURO
R. CARUSO
B. MONARCA
F. MANDELLI

January 1993

Background. The use of fludarabine, an analog of vidarabine with significant lymphocytolytic activit...

Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia

November 2019

10In this study, we evaluated the efficacy of fludarabine (FLU), an adenine nucleoside analogue, in ...

The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders

Lazzarino M
Orlandi E
BALDANTI, FAUSTO
Furione M
Pagnucco G
Astori C
ARCAINI, LUCA
Viglio A
PAULLI, MARCO
Gerna G
Bernasconi C.

January 1999

Fludarabine is effective in chronic lymphocytic leukaemia (CLL) and low-grade non-Hodgltin's lymphom...

Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.

LISO V
MOLICA S
CAPALBO S
POGLIANI E
BATTISTA C
BROCCIA G
MONTILLO M
CUNEO A.
LEONI P
SPECCHIA G
CASTOLDI G

January 2001

BACKGROUND AND OBJECTIVES: Fludarabine (FAMP) is the most active single agent in relapsed and refrac...

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

July 2015

none34noneHallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, ...

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial

Mauro, Francesca Romana
Carella, A. M
Molica, S
Paoloni, F
Liberati, A. M.
Zaja, F
Belsito, V
Cortellezzi, A
Rizzi, R
Tosi, P
Spriano, M
Ferretti, A
Nanni, M
Marinelli, M
De Propris, M. S
Orlando, S. M
Vignetti, Marco
Cuneo, A
Guarini, Anna
Foa, Roberto
Foa, Roberto

January 2017

The activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (F...

Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi.

Ferrario, A.
Merli, F.
Luminari, Stefano
Stelitano, C.
Mannina, D.
Russo, M.
Mazza, P.
Marcheselli, Luigi
Goldaniga, M. C.
Federico, Massimo
Baldini, L.

January 2010

Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has b...

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I\u2013II GIMEMA trial

Mauro, Francesca R
Carella, Angelo M.
Molica, Stefano
Paoloni, Francesca
Liberati, Anna M.
Zaja, Francesco
Belsito, Valeria
Cortellezzi, Agostino
Rizzi, Rita
Tosi, Patrizia
Spriano, Mauro
Ferretti, Antonietta
Nanni, Mauro
Marinelli, Marilisa
De Propris, Maria S.
Orlando, Sonia M.
Vignetti, Marco
Cuneo, Antonio
Guarini, Anna R.
Fo\ue0, Robin

January 2016

he activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (FC...

Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia

November 2019

6nonenoneZAJA, Francesco; Russo D; Marin L; Silvestri F; Ramello M; Baccarani M.Zaja, Francesco; Rus...

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

Sacchi, Stefano
Pozzi, Samantha
Marcheselli, Raffaella
Federico, Massimo
Tucci, A
Merli, F
Orsucci, L
Liberati, M
Vallisa, D
Brugiatelli, M.

January 2007

The current study was conducted to asses the safety profile and clinical activity of rituximab in co...

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas : phase 2 study of the Italian Lymphoma Foundation

A. Ferrario
A. Pulsoni
B. Olivero
G. Rossi
U. Vitolo
A. Tedeschi
F. Merli
L. Rigacci
C. Stelitano
M. Goldaniga
D. Mannina
P. Musto
F. Rossi
E. Gamba
L. Baldini

August 2012

BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell pro...

Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin’s lymphoma

Hendry, L
Bowen, A
Matutes, E
Swansbury, J
Catovsky, D

May 2004

A regimen combining fludarabine, cyclophosphamide and mitoxantrone (FCM) was used to treat 29 patien...

Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients.

SACCHI, Stefano
LUMINARI, Stefano
FEDERICO, Massimo
Alessandra Tucci
Francesco Merli
Loretta Orsucci
Giulia Cervetti
Ubaldo Occhini
Marina Liberati
Giuseppe Tarantini
Vicenzo Callea
Maura Brugiatelli
Vito Michele Lauta
Luca Baldini

January 2002

Both Cyclophsphamide (C) and Fludarabine (F) have individual anti-lymphoma activity and the combinat...

Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma

Zinzani PL.

January 2004

Fludarabine, a purine nucleoside analog, is currently indicated for the first-line treatment of chro...

FLUDARABINE AND CYCLOPHOSPHAMIDE FOR THE TREATMENT OF PATIENTS WITH INDOLENT NON-FOLLICULAR (INFL) B-CELL NON-HODGKIN'S LYMPHOMAS. PRELIMINARY RESULTS OF A PHASE II TRIAL OF THE 'GRUPPO ITALIANO PER LO STUDIO DEI LINFOMI (GISL)

Luminari, Stefano
L., Baldini
M., Brugiatelli
M., Goldaniga
Sacchi, Stefano
A., Bagnulo
F., Merli
C., Stelitano
G., Giglio
Federico, Massimo

January 2004

Introduction: INFL comprises a rather heterogeneous subgroup of lymphomas,including small lymphocyti...

Fludarabine and prednisone in pretreated refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages

G. DE ROSSI
F. MAURO
R. CARUSO
B. MONARCA
F. MANDELLI

January 1993

Background. The use of fludarabine, an analog of vidarabine with significant lymphocytolytic activit...

Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia

November 2019

10In this study, we evaluated the efficacy of fludarabine (FLU), an adenine nucleoside analogue, in ...

The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders

Lazzarino M
Orlandi E
BALDANTI, FAUSTO
Furione M
Pagnucco G
Astori C
ARCAINI, LUCA
Viglio A
PAULLI, MARCO
Gerna G
Bernasconi C.

January 1999

Fludarabine is effective in chronic lymphocytic leukaemia (CLL) and low-grade non-Hodgltin's lymphom...

Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.

LISO V
MOLICA S
CAPALBO S
POGLIANI E
BATTISTA C
BROCCIA G
MONTILLO M
CUNEO A.
LEONI P
SPECCHIA G
CASTOLDI G

January 2001

BACKGROUND AND OBJECTIVES: Fludarabine (FAMP) is the most active single agent in relapsed and refrac...

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

July 2015

none34noneHallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, ...

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial

Mauro, Francesca Romana
Carella, A. M
Molica, S
Paoloni, F
Liberati, A. M.
Zaja, F
Belsito, V
Cortellezzi, A
Rizzi, R
Tosi, P
Spriano, M
Ferretti, A
Nanni, M
Marinelli, M
De Propris, M. S
Orlando, S. M
Vignetti, Marco
Cuneo, A
Guarini, Anna
Foa, Roberto
Foa, Roberto

January 2017

The activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (F...

Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi.

Ferrario, A.
Merli, F.
Luminari, Stefano
Stelitano, C.
Mannina, D.
Russo, M.
Mazza, P.
Marcheselli, Luigi
Goldaniga, M. C.
Federico, Massimo
Baldini, L.

January 2010

Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has b...

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I\u2013II GIMEMA trial

Mauro, Francesca R
Carella, Angelo M.
Molica, Stefano
Paoloni, Francesca
Liberati, Anna M.
Zaja, Francesco
Belsito, Valeria
Cortellezzi, Agostino
Rizzi, Rita
Tosi, Patrizia
Spriano, Mauro
Ferretti, Antonietta
Nanni, Mauro
Marinelli, Marilisa
De Propris, Maria S.
Orlando, Sonia M.
Vignetti, Marco
Cuneo, Antonio
Guarini, Anna R.
Fo\ue0, Robin

January 2016

he activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (FC...

Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia

November 2019

6nonenoneZAJA, Francesco; Russo D; Marin L; Silvestri F; Ramello M; Baccarani M.Zaja, Francesco; Rus...

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

Sacchi, Stefano
Pozzi, Samantha
Marcheselli, Raffaella
Federico, Massimo
Tucci, A
Merli, F
Orsucci, L
Liberati, M
Vallisa, D
Brugiatelli, M.

January 2007

The current study was conducted to asses the safety profile and clinical activity of rituximab in co...

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas : phase 2 study of the Italian Lymphoma Foundation

A. Ferrario
A. Pulsoni
B. Olivero
G. Rossi
U. Vitolo
A. Tedeschi
F. Merli
L. Rigacci
C. Stelitano
M. Goldaniga
D. Mannina
P. Musto
F. Rossi
E. Gamba
L. Baldini

August 2012

BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell pro...

Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas

Abstract

Extracted data

Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas

Abstract

Extracted data

Related items

Related items